Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
Katherine Foster(The University of Texas MD Anderson Cancer Center), Anil K. Sood(The University of Texas MD Anderson Cancer Center), Shannon N. Westin(The University of Texas MD Anderson Cancer Center), Reid T. Powell(Texas A&M Health Science Center), Mary Sobieski(Texas A&M University), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Clifford Stephan(Texas A&M Health Science Center), Nghi D. Nguyen(Texas A&M University), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Ashwani Bahl, Santosh K. Dasari(National Institute of Animal Biotechnology)
Cited by 1
Related Papers
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
|Nature Medicine|2023|508